Helex $3.5M Seed Battle Card
Dr. Poulami Chaudhuri just closed a $3.5M seed round. Use this battle card to pitch LNP scale-up & AI analytics, fill your pipeline and close the deal.
Published on
Do not index
Do not index
🚀 Battle Card: Helex
Quick trigger:
👤 Decision Maker in the News
- Dr. Poulami Chaudhuri, Co-Founder & CEO 📧 poulami.chaudhuri@helex.bio
💡 Why It Matters
- The $3.5M injection accelerates advanced LNP and AI drug design for targeted kidney disease therapies—perfect timing for a Helex sales trigger outreach. → Source
🎯 Core Pain Point
- Achieving precise LNP delivery to renal cells
- Integrating AI-designed candidates into clinical pipelines
💰 What to Pitch
- Primary: LNP characterization & scale-up → consistent payload delivery at scale—timed with this Helex sales trigger
- Expansion: AI-driven predictive analytics → accelerated lead discovery cycles to leverage the Helex sales trigger
🗺️ Quick Context
- HQ: New York, NY, USA
- Employees: ≈ 25
- Rev: ≈ $0.5M
- Website: helex.bio
🤼 Competitive Intel
*Which other vendors you’ll probably face to win Helex’s business.*
- Moderna — LNP Drug Delivery
- Unique edge: Proprietary ionizable lipid platforms at scale
- Evaluated by R&D for formulation robustness
- BioNTech — LNP Drug Delivery
- Unique edge: mRNA/LNP co-development expertise
- Evaluated by CMO for cGMP supply chains
- Alnylam Pharmaceuticals — RNAi/LNP Delivery
- Unique edge: Clinical-stage siRNA delivery track record
- Evaluated by Clinical Ops for safety data
- Atomwise — AI-driven Drug Design
- Unique edge: Deep learning–based molecule screening
- Evaluated by Head of Discovery for hit-rate improvement
- Insilico Medicine — AI-driven Drug Design
- Unique edge: Generative chemistry for novel scaffolds
- Evaluated by VP R&D for lead-generation speed
✅ Do-Now Checklist
Connect with Dr. Poulami Chaudhuri on email and LinkedIn
Generate email + DM with the Copy-My-Prompt block (Step 7) and send first touch
Schedule follow-ups in CRM (Day 3 & Day 10)
Next Step
Stay on every Helex sales trigger—subscribe now.
Subscribe to NewsletterForLeads
🧠 Copy My Prompt for Personalized Cold Outreach
────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY = ❑<your company>❑
OFFER_BRIEF = ❑<1-line value>❑
PROOF_METRIC = ❑<metric>❑
CTA_STYLE = ❑quick_call | case_study❑
TONE = ❑friendly | punchy❑
────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME = Poulami
COMPANY = Helex
DEPT = R&D
SIZE = 25
BOTTLENECK = Achieving precise LNP delivery to renal cells
EVENT = Pulls In $3.5M Seed Financing Round
DETAIL = Pulls In $3.5M Seed Financing Round
PAIN = Achieving precise LNP delivery to renal cells
SRC = https://vcnewsdaily.com/helex/venture-capital-funding/kpgfbjsttt
SIM_CO = Moderna
WIN_METRIC = 30% increase in payload delivery consistency
NEXT_SIZE = 50
EMP_EST = ≈ 25
REV_EST = ≈ $0.5M
────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.
Validate any ≈ guesses via SRC.
EMAIL (keep breaks):
Subject: 25-person R&D
Poulami—noticed your R&D team is ≈ 25.
That’s when Achieving precise LNP delivery to renal cells slows growth.
We helped Moderna fix this with ≈ TBD.
Result: 30% increase in payload delivery consistency.
<<CTA_STYLE=="quick_call" ? "Quick call?" : "Want the 2-min recap?">>
PS—next bottleneck hits ≈ 50.
DM ≤45 words, TONE:
Saw your post about Pulls In $3.5M Seed Financing Round — Achieving precise LNP delivery to renal cells.
≈ TBD. ≈ TBD.
<<CTA_STYLE=="quick_call" ? "Quick chat?" : "Send case study?">>